Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027.
FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.
In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that raises yield approximately 400%.

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between clinical validation and market adoption. Regentis Biomaterials (NYSE American: RGNT) is attempting exactly that, advancing its GelrinC(R) cartilage repair platform along a U.S. clinical track and a European commercial track and scaling of manufacturing at the same time.

At a glance

Company: Regentis Biomaterials
Ticker: NYSE American: RGNT
Announcement: Regulatory

Key figures

SAGE study enrollment: 50%
Recruitment completion target: third quarter of 2026
Expected PMA process start: by the end of 2027
Patients in initial trial group: first 40 patients
Reported manufacturing yield increase: approximately 400%
Implant procedure duration: roughly 10 minutes

Products and programs

GelrinC

The U.S. Program Approaches Its Defining Milestone

GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Rather than harvesting cells from the patient, expanding them in a laboratory and implanting them during a second surgery, GelrinC arrives ready to use and is implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, then…

In brief

Regentis Biomaterials says enrollment has exceeded 50% in the pivotal Phase III SAGE study of GelrinC, a cell-free hydrogel implant for knee cartilage defects. The company is aiming to complete recruitment in the third quarter of 2026 and expects to begin the PMA process by the end of 2027. It reports that the FDA approved a single-arm protocol using historical microfracture control data owned by Regentis, and that the first 40 trial participants closely resemble that control group. In Europe, GelrinC has CE Mark approval, surgeon training began at Humanitas Research Hospital in Milan, and the company says a manufacturing process approved recently increases yield by approximately 400%. The release describes U.S. clinical, European commercial and manufacturing work proceeding in parallel.

Key takeaways

Regentis reports that enrollment in the SAGE Phase III study has passed 50%.
Recruitment is targeted for completion in the third quarter of 2026; the company expects a PMA process to start by the end of 2027.
The FDA approved a single-arm protocol using historical microfracture control data owned by Regentis.
European surgeon training began at Humanitas Research Hospital in Milan, where GelrinC already has CE Mark approval.
The company says an approved manufacturing process raises yield by approximately 400%.

SEC filings

Earlier from Regentis Biomaterials

Back to News Center